Literature DB >> 3773199

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

J Stamler, D Wentworth, J D Neaton.   

Abstract

The 356,222 men aged 35 to 57 years, who were free of a history of hospitalization for myocardial infarction, screened by the Multiple Risk Factor Intervention Trial (MRFIT) in its recruitment effort, constitute the largest cohort with standardized serum cholesterol measurements and long-term mortality follow-up. For each five-year age group, the relationship between serum cholesterol and coronary heart disease (CHD) death rate was continuous, graded, and strong. For the entire group aged 35 to 57 years at entry, the age-adjusted risks of CHD death in cholesterol quintiles 2 through 5 (182 to 202, 203 to 220, 221 to 244, and greater than or equal to 245 mg/dL [4.71 to 5.22, 5.25 to 5.69, 5.72 to 6.31, and greater than or equal to 6.34 mmol/L]) relative to the lowest quintile were 1.29, 1.73, 2.21, and 3.42. Of all CHD deaths, 46% were estimated to be excess deaths attributable to serum cholesterol levels 180 mg/dL or greater (greater than or equal to 4.65 mmol/L), with almost half the excess deaths in serum cholesterol quintiles 2 through 4. The pattern of a continuous, graded, strong relationship between serum cholesterol and six-year age-adjusted CHD death rate prevailed for nonhypertensive nonsmokers, nonhypertensive smokers, hypertensive nonsmokers, and hypertensive smokers. These data of high precision show that the relationship between serum cholesterol and CHD is not a threshold one, with increased risk confined to the two highest quintiles, but rather is a continuously graded one that powerfully affects risk for the great majority of middle-aged American men.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3773199

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  299 in total

Review 1.  Cholesterol lowering and coronary artery disease: mechanisms of risk reduction.

Authors:  R A Archbold; A D Timmis
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Goals of statin therapy: three viewpoints.

Authors:  Gilbert R Thompson; Christopher J Packard; Neil J Stone
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 3.  The effect of n-3 fatty acids on low density lipoprotein subfractions.

Authors:  B A Griffin
Journal:  Lipids       Date:  2001       Impact factor: 1.880

Review 4.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 5.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 6.  Risk factor thresholds: their existence under scrutiny.

Authors:  M R Law; N J Wald
Journal:  BMJ       Date:  2002-06-29

7.  Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes.

Authors:  Mrinalini Kulkarni; Peter D Reaven
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 8.  Multi-bed vascular disease: past, present, and future.

Authors:  William C Dixon; Robert A Harrington
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

9.  A prospective study of hyperlipidemia as a pathogenic factor in sudden hearing loss.

Authors:  D Ullrich; G Aurbach; C Drobik
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

Review 10.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.